TrialCancer immunology, immunotherapy : CII2015

Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.

Masanori Noguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.